ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Accepted Preprint first posted online on 4 June 2008

Endocrine-Related Cancer 2008;15:657.

DOI: 10.1677/ERC-08-0019
Copyright © 2008 by the Society for Endocrinology.
This Article
Right arrow Accepted manuscript (PDF)
Right arrow Erratum
Right arrow All Versions of this Article:
ERC-08-0019v1
15/3/657    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Languino, L.
Right arrow Articles by Li, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Languino, L.
Right arrow Articles by Li, J.
REVIEW

Integrins in Prostate Cancer Progression

 Lucia Languino, Hira Goel, Sophia Kogan and Jing Li

L Languino, Cancer Biology, Umass Medical School, Worcester, 01605, United States
H Goel, United States
S Kogan, United States
J Li, Cancer Biology, U Massachusetts, Worcester, United States

Correspondence: Lucia Languino, Email: lucia.languino{at}umassmed.edu

Abstract

Integrins, which are transmembrane receptors for extracellular matrix proteins, play a key role in cell survival, proliferation, migration, gene expression and activation of growth factor receptors. Their functions and expression are deregulated in several types of cancer, including prostate cancer. We review in this article the role of integrins in prostate cancer progression and their potential as therapeutic targets.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the Society for Endocrinology.